EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic
gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma
and colorectal cancer.